<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a consecutive series of 59 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who underwent reduced-intensity hematopoietic stem cell transplantation (RI-HSCT) with fludarabine/melphalan conditioning and tacrolimus/<z:chebi fb="0" ids="9168">sirolimus</z:chebi>-based GVHD prophylaxis </plain></SENT>
<SENT sid="1" pm="."><plain>Two-year OS, EFS, and relapse incidences were 75.1%, 65.2%, and 20.9%, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>The cumulative incidence of non-relapse mortality at 100 days, 1 year, and 2 years was 3.4%, 8.5%, and 10.5%, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>The incidence of grade II-IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD was 35.4%; grade III-IV was 18.6% </plain></SENT>
<SENT sid="4" pm="."><plain>Forty of 55 evaluable patients developed <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD; of these 35 were extensive grade </plain></SENT>
<SENT sid="5" pm="."><plain>This RI-HSCT protocol produces encouraging outcomes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, and tacrolimus/<z:chebi fb="0" ids="9168">sirolimus</z:chebi>-based GVHD prophylaxis may contribute to that promising result </plain></SENT>
</text></document>